In Brief: Gene therapy public conference
Gene therapy public conference: FDA will sponsor a public conference July 11-12 on gene therapy development and evaluation of Phase I products and vector development, according to an April 29 Federal Register notice. The conference will touch on the investigational new drug process, points-to-consider documents and resources available from the National Institutes of Health to bring products into clinical trials. The conference will be held at the NIH Natcher Auditorium in Bethesda, Md., beginning at 8 a.m. both days...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth